Clinical Trial

Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions

Completed
View on ClinicalTrials.gov →
Summary
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma with vascular invasions
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-12.
Status change: Recruiting → Completed 2026-05-07
Trial Details
NCT Number NCT06881446
Lead Sponsor Zhongda Hospital
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 2,651 participants
Start Date 2018-06-01
Primary Completion 2025-03-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-11